6533b822fe1ef96bd127d69a

RESEARCH PRODUCT

Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures.

Federico V. PallardóMaria Rosa FittipaldiMarco TrifuoggiLuca TianoMaria ToscanesiAlex LyakhovichGiovanni Pagano

subject

0301 basic medicineAgingAntioxidantUbiquinonemedicine.medical_treatmentmitochondrial nutrientsReviewoptic neuropathiesType 2 diabetesPharmacologyMitochondrionmedicine.disease_causeAntioxidantslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineCardiovascular Diseaseoxidative stressaging-related disorderslcsh:QH301-705.5SpectroscopyThioctic AcidMitochondrial nutrientNeurodegenerative DiseasesGeneral MedicineComputer Science ApplicationsMitochondriaCardiovascular DiseasesAntioxidantmedicine.drugHumanCatalysisAging-related disorderCell LineInorganic Chemistry03 medical and health sciencesCarnitinemedicineAnimalsHumansMicrobiomeCarnitinePhysical and Theoretical ChemistryMolecular BiologyCoenzyme Q10business.industryAnimalOrganic ChemistryOxidative Stremedicine.diseaseClinical trial030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryDiabetes Mellitus Type 2MicrobiomeOptic neuropathiebusinessMitochondrial dysfunction030217 neurology & neurosurgeryOxidative stress

description

A number of aging-related disorders (ARD) have been related to oxidative stress (OS) and mitochondrial dysfunction (MDF) in a well-established body of literature. Most studies focused on cardiovascular disorders (CVD), type 2 diabetes (T2D), and neurodegenerative disorders. Counteracting OS and MDF has been envisaged to improve the clinical management of ARD, and major roles have been assigned to three mitochondrial cofactors, also termed mitochondrial nutrients (MNs), i.e., alpha-lipoic acid (ALA), Coenzyme Q10 (CoQ10), and carnitine (CARN). These cofactors exert essential-and distinct-roles in mitochondrial machineries, along with strong antioxidant properties. Clinical trials have mostly relied on the use of only one MN to ARD-affected patients as, e.g., in the case of CoQ10 in CVD, or of ALA in T2D, possibly with the addition of other antioxidants. Only a few clinical and pre-clinical studies reported on the administration of two MNs, with beneficial outcomes, while no available studies reported on the combined administration of three MNs. Based on the literature also from pre-clinical studies, the present review is to recommend the design of clinical trials based on combinations of the three MNs.

https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15044